Schauer Philip R, Bhatt Deepak L, Kirwan John P, Wolski Kathy, Aminian Ali, Brethauer Stacy A, Navaneethan Sankar D, Singh Rishi P, Pothier Claire E, Nissen Steven E, Kashyap Sangeeta R
From the Bariatric and Metabolic Institute (P.R.S., A.A., S.A.B.), Lerner Research Institute (J.P.K.), Cleveland Clinic Coordinating Center for Clinical Research (K.W., C.E.P., S.E.N.), Cole Eye Institute (R.P.S.), and Endocrinology Institute (S.R.K.), Cleveland Clinic, Cleveland; Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); and the Section of Nephrology, Baylor College of Medicine, Houston (S.D.N.).
N Engl J Med. 2017 Feb 16;376(7):641-651. doi: 10.1056/NEJMoa1600869.
Long-term results from randomized, controlled trials that compare medical therapy with surgical therapy in patients with type 2 diabetes are limited.
We assessed outcomes 5 years after 150 patients who had type 2 diabetes and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 27 to 43 were randomly assigned to receive intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy. The primary outcome was a glycated hemoglobin level of 6.0% or less with or without the use of diabetes medications.
Of the 150 patients who underwent randomization, 1 patient died during the 5-year follow-up period; 134 of the remaining 149 patients (90%) completed 5 years of follow-up. At baseline, the mean (±SD) age of the 134 patients was 49±8 years, 66% were women, the mean glycated hemoglobin level was 9.2±1.5%, and the mean BMI was 37±3.5. At 5 years, the criterion for the primary end point was met by 2 of 38 patients (5%) who received medical therapy alone, as compared with 14 of 49 patients (29%) who underwent gastric bypass (unadjusted P=0.01, adjusted P=0.03, P=0.08 in the intention-to-treat analysis) and 11 of 47 patients (23%) who underwent sleeve gastrectomy (unadjusted P=0.03, adjusted P=0.07, P=0.17 in the intention-to-treat analysis). Patients who underwent surgical procedures had a greater mean percentage reduction from baseline in glycated hemoglobin level than did patients who received medical therapy alone (2.1% vs. 0.3%, P=0.003). At 5 years, changes from baseline observed in the gastric-bypass and sleeve-gastrectomy groups were superior to the changes seen in the medical-therapy group with respect to body weight (-23%, -19%, and -5% in the gastric-bypass, sleeve-gastrectomy, and medical-therapy groups, respectively), triglyceride level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, and 7%), use of insulin (-35%, -34%, and -13%), and quality-of-life measures (general health score increases of 17, 16, and 0.3; scores on the RAND 36-Item Health Survey ranged from 0 to 100, with higher scores indicating better health) (P<0.05 for all comparisons). No major late surgical complications were reported except for one reoperation.
Five-year outcome data showed that, among patients with type 2 diabetes and a BMI of 27 to 43, bariatric surgery plus intensive medical therapy was more effective than intensive medical therapy alone in decreasing, or in some cases resolving, hyperglycemia. (Funded by Ethicon Endo-Surgery and others; STAMPEDE ClinicalTrials.gov number, NCT00432809 .).
比较2型糖尿病患者药物治疗与手术治疗的随机对照试验的长期结果有限。
我们评估了150例2型糖尿病且体重指数(BMI;体重千克数除以身高米数的平方)为27至43的患者,随机分配接受单纯强化药物治疗或强化药物治疗加Roux-en-Y胃旁路手术或袖状胃切除术5年后的结果。主要结局是糖化血红蛋白水平达到6.0%或更低,无论是否使用糖尿病药物。
150例接受随机分组的患者中,1例在5年随访期内死亡;其余149例患者中的134例(90%)完成了5年随访。基线时,134例患者的平均(±标准差)年龄为49±8岁,66%为女性,平均糖化血红蛋白水平为9.2±1.5%,平均BMI为37±3.5。5年后,单纯接受药物治疗的38例患者中有2例(5%)达到主要终点标准,而接受胃旁路手术的49例患者中有14例(29%)(未校正P=0.01,校正P=0.03,意向性分析中P=0.08),接受袖状胃切除术的47例患者中有11例(23%)(未校正P=0.03,校正P=0.07,意向性分析中P=0.17)。接受手术治疗的患者糖化血红蛋白水平较基线的平均降低百分比高于单纯接受药物治疗的患者(分别为2.1%和0.3%,P=0.003)。5年后,胃旁路手术组和袖状胃切除术组相对于基线的变化在体重(胃旁路手术组、袖状胃切除术组和药物治疗组分别为-23%、-19%和-5%)、甘油三酯水平(-40%、-29%和-8%)、高密度脂蛋白胆固醇水平(32%、30%和7%)、胰岛素使用(-35%、-34%和-13%)以及生活质量指标(一般健康评分分别增加17、16和0.3;兰德36项健康调查评分范围为0至100,分数越高表明健康状况越好)方面优于药物治疗组(所有比较P<0.05)。除一次再次手术外,未报告重大晚期手术并发症。
5年结局数据显示,在BMI为27至43的2型糖尿病患者中,减重手术加强化药物治疗在降低或在某些情况下解决高血糖方面比单纯强化药物治疗更有效。(由爱惜康内镜外科公司等资助;STAMPEDE临床试验注册号,NCT00432809。)